B7-33
Trending

B7-33

Single-chain relaxin B-chain analog targeting the RXFP1 receptor. Studied for anti-fibrotic effects in cardiac, renal, and pulmonary fibrosis models without

Anti-AgingSkin
● In Stock

Buy more, save more

1+ vials
−5%
3+ vials
−10%
5+ vials
−20%
10+ vials

Total Price

$110

For research & laboratory use only. Not for human consumption.

Half-Life

Unknown

Administration Route

Subcutaneous injection

Anti-Fibrotic Peptide

Relaxin/RXFP1 agonist reduces organ fibrosis

Cardiac & Pulmonary

Studied for heart failure, pulmonary fibrosis, and kidney disease

Anti-Inflammatory

Reduces TGF-β driven fibroblast activation in chronic disease

Effect Profile

Cellular Longevity

0%

Collagen Synthesis

0%

Oxidative Protection

0%

Energy Restoration

0%

Mechanism of Action

B7-33 is a truncated, single-chain analog of human relaxin-2 that selectively binds and activates RXFP1 (relaxin family peptide receptor 1). RXFP1 activation reduces collagen production by cardiac and renal fibroblasts, promotes matrix metalloproteinase expression for fibrous tissue remodelling, and inhibits TGF-beta-driven fibrogenic pathways. Unlike full relaxin-2, B7-33 has minimal activity at RXFP2 (the receptor mediating relaxin effects on the reproductive tract), providing a more targeted anti-fibrotic profile.

Scientific Research

Product FAQs

Related Products

Cart

Your cart is empty